FILANA THERAPEUTICS INCFLNA
ASignal's systematic analysis rates FLNA as Neutral.
Reflects the latest available analysis · analyzed Sep 25, 2026
The case on FLNA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Positive free cash flow ($3.98M)
- Zero debt and strong liquidity (current ratio 2.08x)
- Cash-rich balance sheet ($82.68M cash)
- MACD histogram turning positive
- Price above Bollinger Bands lower band with room to rebound
- Negative return on equity (-55.78%)
- Negative operating cash flow (-$28.70M)
- Zero profit and gross margins
- High EV/EBITDA (3.57x) for a pre-revenue biotech
- Low market cap ($37.29M) indicating high risk
- Lack of revenue and earnings growth data
See the full verdict on FLNA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes FLNA
Most investors never get a second opinion, let alone several. ASignal runs FLNA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.